Allianz Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Allianz Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-191,100	Closed	-$1.66M	–	2211
2024 Q1	$1.66M	Buy	+191,100	New	+$1.29M	﹤0.01%	1245
2023 Q3	–	Sell	-33,079	Closed	-$411K	–	2237
2023 Q2	$411K	Sell	33,079 -36,602	-53%	-$494K	﹤0.01%	1785
2023 Q1	$976K	Buy	+69,681	New	+$1M	﹤0.01%	1695
2022 Q3	–	Sell	-64,305	Closed	-$1.83M	–	2038
2022 Q2	$1.83M	Buy	64,305 +23,677	+58%	+$750K	﹤0.01%	1454
2022 Q1	$1.43M	Sell	40,628 -17,661	-30%	-$592K	﹤0.01%	1718
2021 Q4	$2.44M	Buy	58,289 +22,241	+62%	+$901K	﹤0.01%	1533
2021 Q3	$1.77M	Sell	36,048 -7,572	-17%	-$369K	﹤0.01%	1696
2021 Q2	$1.82M	Sell	43,620 -671,187	-94%	-$26M	﹤0.01%	1501
2021 Q1	$25.5M	Sell	714,807 -401,543	-36%	-$13.3M	0.02%	535
2020 Q4	$31.3M	Buy	+1,116,350	New	+$31.1M	0.03%	478

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allianz Asset Management's MRVI Position: Q2 2024 in Review

Allianz Asset Management sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 191,100 shares — an estimated $1.66M sold.

Allianz Asset Management first reported a position in MRVI in Q4 2020 and held it in 10 quarters. The position peaked at $31.3M in Q4 2020. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

Allianz Asset Management reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
Allianz Asset Management sold 191,100 Maravai LifeSciences shares in Q2 2024, an estimated $1.66M.
Allianz Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 10 quarters.
Allianz Asset Management's Maravai LifeSciences position peaked at $31.3M in Q4 2020.
206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on Allianz Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.